RERannveig Sakshaug Eldholm

Rannveig Sakshaug Eldholm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rannveig Sakshaug Eldholm has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

  • Ingvild Saltvedt

    Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway

    10 shared publications
  • Knut Engedal

    Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway

    6 shared publications
  • Karin Persson

    The Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway

    5 shared publications
  • Anne-Brita Knapskog

    Department og Geriatric Medicine, Oslo University Hospital

    4 shared publications
  • Geir Selbæk

    Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway

    4 shared publications
  • Geir Selbæk

    Norwegian National Centre for Ageing and Health Vestfold Hospital Trust Tønsberg Norway

    4 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology

    by Jun-Ping Pan, Ping-Jie Wang, Jianying Zhang, Anne-Brita Knapskog, Leiv Otto Watne, He-Ling Wang, Maria Jose Lagartos-Donate, Sofie Lautrup, Li-Peng Mao, Qian Wang, et al.

    ULK1 (Atg1) initiates macroautophagy and mitophagy, which support neuronal growth and survival, yet how this pathway is disrupted in aging and Alzheimer's disease (AD) remains unclear. Here we report reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316). In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality. Mechanistically, ULK1 upregulation increases autophagy and PINK1-, FUNDC1- and AMBRA1-associated mitophagy; higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy. We propose that age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD and identify ULK1 as a potential therapeutic target.


  • Open Access

    Potentially inappropriate medications related to two-year progression of mild cognitive impairment and dementia

    by Hege Kersten, Maria L. Barca, Rannveig Sakshaug Eldholm, Karin Persson, Lara Thomasgaard, Keson Jaioun, Ingvild Saltvedt, Geir Selbaek, Knut Engedal

    Purpose: To document use and impact of potentially inappropriate medications on two-year progression of dementia in individuals with cognitive declines. Methods: A retrospective study of 397 patients with Mild Cognitive Impairment (MCI) or dementia diagnosed and followed-up in outpatient memory clinics in Norway during 2009 − 18. Beers (2019)- and STOPP-2 criteria were used to identify Potentially Inappropriate Medications (PIMcogs) in individuals with cognitive impairments at baseline and two-year-follow-up. PIMcog use in terms of dementia severity, cognitive function, and neuropsychiatric and depressive symptoms were analyzed in regression models. Results: The prevalence of PIMcogs increased from 16% at baseline to 23% at follow-up. PIMcog users were more likely to be women (63.5%), and they used more drugs, with a median of 5 drugs at baseline and 4 drugs at follow-up, compared to non-users who had a median of 3 used drugs at both time points. PIMcog users had higher median Neuropsychiatric Inventory severity sum scores (6 [3.0–11.0] versus 4.0 [2.0–7.0]) and median Cornell Scale for Depression in Dementia scores (6.5 [3.0–11.0] versus 4.0 [1.0–7.0]) compared to non-users at follow-up ( p ≤ 0.002). PIMcog users exhibited more severe dementia, with a Clinical Dementia Rate-Sum of Boxes (CDR-SB) score of 7.0 (4.0–13.0) compared to 6.0 (3.5–10.0) in non-users. The median annual increase in CDR-SB was one unit, and PIMcog use at follow-up was significantly associated with more rapid progression of dementia severity. Conclusion: Faster dementia progression was documented among PIMcog users although, the prevalence of PIMcogs was generally low in Norwegian memory clinic patients with cognitive impairments.


  • Open Access

    Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with delirium

    by Mari Aksnes, Mari Haavig Schibstad, Farrukh Abbas Chaudhry, Bjørn Erik Neerland, Gideon Caplan, Ingvild Saltvedt, Rannveig S. Eldholm, Marius Myrstad, Trine Holt Edwin, Karin Persson, et al.

    Background: The aetiology of delirium is not known, but pre-existing cognitive impairment is a predisposing factor. Here we explore the associations between delirium and cerebrospinal fluid (CSF) levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), proteins with important roles in both acute injury and chronic neurodegeneration. Methods: Using a 13-plex Discovery Assay®, we quantified CSF levels of 9 MMPs and 4 TIMPs in 280 hip fracture patients (140 with delirium), 107 cognitively unimpaired individuals, and 111 patients with Alzheimer’s disease dementia. The two delirium-free control groups without acute trauma were included to unravel the effects of acute trauma (hip fracture), dementia, and delirium. Results: Here we show that delirium is associated with higher levels of MMP-2, MMP-3, MMP-10, TIMP-1, and TIMP-2; a trend suggests lower levels of TIMP-4 are also associated with delirium. Most delirium patients had pre-existing dementia and low TIMP-4 is the only marker associated with delirium in adjusted analyses. MMP-2, MMP-12, and TIMP-1 levels are clearly higher in the hip fracture patients than in both control groups and several other MMP/TIMPs are impacted by acute trauma or dementia status. Conclusions: Several CSF MMP/TIMPs are significantly associated with delirium in hip fracture patients, but alterations in most of these MMP/TIMPs could likely be explained by acute trauma and/or pre-fracture dementia. Low levels of TIMP-4 appear to be directly associated with delirium, and the role of this marker in delirium pathophysiology should be further explored.


  • Open Access

    Changes in sedentary behavior in the chronic phase following stroke

    by Tone Svalbjørg, Torunn Askim, Ingvild Saltvedt, Katinka Alme, Stian Lydersen, Rannveig Eldholm


  • Open Access

    Associations of Serum Vitamin D With Dental Caries and Periodontitis: The HUNT Study

    by Ernest Obeng Asante, Yue Chen, Rannveig Sakshaug Eldholm, Hedda Høvik, Marit Kolberg, Håvard Kjesbu Skjellegrind, Roya Torabi-Gaarden, Xiao-Mei Mai, Yi-Qian Sun


  • Open Access

    Vitamin D Status Over Time and Cognitive Function in Norwegian Older Adults: A Prospective Cohort of the HUNT Study

    by Ernest Obeng Asante, X.-M. Mai, R. S. Eldholm, H. K. Skjellegrind, M. Kolberg, B. M. Brumpton, G. Selbœk, Y. Chen, Y.-Q. Sun


  • Open Access

    Brain Morphometric Correlates of Depressive Symptoms among Patients with and without Dementia

    by Maria Lage Barca, Dag Alnæs, Knut Engedal, Karin Persson, Rannveig Sakshaug Eldholm, Nikias Siafarikas, Ina Selseth Almdahl, Maria Stylianou-Korsnes, Ingvild Saltvedt, Geir Selbæk, et al.

    Introduction: Findings regarding brain morphometry among patients with dementia and concomitant depressive symptoms have been inconsistent. Thus, the aim of the present study was to test the hypothesis that dementia and concomitant depressive symptoms are associated with structural brain changes in the temporal lobe measured with structural magnetic resonance imaging (MRI). Methods: A sample of 492 patients from Norwegian memory clinics (n = 363) and Old Age Psychiatry services (n = 129) was studied. The assessment included the Cornell Scale for Depression in Dementia (CSDD), Instrumental Activities of Daily Living Scale, Mini Mental State Examination, and MRI of the brain, processed with FreeSurfer to derive ROI measures of cortical thickness, volume, and area using the Desikan-Killiany parcellation, as well as subcortical volumes. Dementia was diagnosed according to ICD-10 research criteria. Correlates of brain morphometry using multiple linear regression were examined. Results: Higher scores on the CSDD were associated with larger cortical volume (β = 0.125; p value = 0.003) and area of the left isthmus of the cingulate gyrus (β = 0.151; p value = <0.001) across all patients. Inclusion of an interaction term (dementia × CSDD) revealed a smaller area in the left temporal pole (β = −0.345; p value = 0.001) and right-transverse temporal cortex (β = −0.321; p value = 0.001) in patients with dementia and depressive symptoms. Discussion/Conclusion: We confirm the previous findings of structural brain changes in temporal regions among patients with dementia and concomitant depressive symptoms. This may contribute to a better understanding of the mechanisms underlying depression in dementia. To the best of our knowledge, this is the largest study conducted on this topic to date.


  • Open Access

    Symptom profiles in patients with Alzheimer’s disease with and without concomitant cerebrovascular disease: an observational study

    by Rannveig Sakshaug Eldholm, Maria Lage Barca, Karin Persson, Anne-Brita Knapskog, Knut Engedal, Geir Selbæk, Eva Skovlund, Ingvild Saltvedt

    Background: Diagnostic criteria of Alzheimer’s disease (AD) and vascular cognitive impairment (VCI) describe different cognitive profiles. AD patients often have concomitant cerebrovascular disease (CVD) and these patients could therefore be expected to display symptoms of both AD and VCI. AD patients with concomitant CVD display symptoms of cognitive impairment with less AD pathology than those without CVD. Medial temporal atrophy (MTA) on magnetic resonance imaging (MRI) is a biomarker of neurodegeneration in AD, and we would expect less MTA in AD patients with CVD. The first aim was to examine whether there were differences in the results of cognitive tests for memory, executive function, and processing speed, or in depressive symptoms, between AD patients with and without CVD. Secondly, to assess whether MTA on MRI is more pronounced among AD patients without CVD. Methods: A total of 192 AD patients with amnestic mild cognitive impairment or mild dementia underwent cognitive assessment and depression screening. Cerebral MRIs were assessed for MTA, white matter hyperintensities, and lacunar and cortical infarcts. CVD was defined as the presence of white matter hyperintensities Fazekas scale ≥2 or any infarct. To study the effect of CVD, several multiple linear regression analyses were carried out using CVD adjusted for age and sex as the independent variable, and cognitive test scores, depression scores, and MTA as dependent variables. Results: Mean age was 72.2 (SD 8.3) years. The number of AD patients with and without concomitant CVD was 121 and 71, respectively. The group with CVD scored significantly lower on tests of attention, executive function and immediate recall compared with the group without CVD. In analyses controlled for age and sex, concomitant CVD was not associated with significant differences in any cognitive test nor in depressive symptoms. A statistically significant association between AD with concomitant CVD and more pronounced MTA was identified. Conclusions: The results indicate that cognitive test profiles, depressive symptoms, and MTA scores cannot be used to distinguish AD patients with and without CVD.

  • Open Access

    Association between vascular comorbidity and progression of Alzheimer’s disease: a two-year observational study in Norwegian memory clinics

    by Rannveig Sakshaug Eldholm, Karin Persson, Maria Lage Barca, Anne-Brita Knapskog, Lena Cavallin, Knut Engedal, Geir Selbaek, Eva Skovlund, Ingvild Saltvedt

    Vascular risk factors increase the risk of Alzheimer’s disease (AD), but there is limited evidence on whether comorbid vascular conditions and risk factors have an impact on disease progression. The aim of this study was to examine the association between vascular disease and vascular risk factors and progression of AD. In a longitudinal observational study in three Norwegian memory clinics, 282 AD patients (mean age 73.3 years, 54% female) were followed for mean 24 (16–37) months. Vascular risk factors and vascular diseases were registered at baseline, and the vascular burden was estimated by the Framingham Stroke Risk Profile (FSRP). Cerebral medical resonance images (MRIs) were assessed for white matter hyperintensities (WMH), lacunar and cortical infarcts. The associations between vascular comorbidity and progression of dementia as measured by annual change in Clinical Dementia Rating Sum of Boxes (CDR-SB) scores were analysed by multiple regression analyses, adjusted for age and sex. Hypertension occurred in 83%, hypercholesterolemia in 53%, diabetes in 9%, 41% were overweight, and 10% were smokers. One third had a history of vascular disease; 16% had heart disease and 15% had experienced a cerebrovascular event. MRI showed lacunar infarcts in 16%, WMH with Fazekas score 2 in 26%, and Fazekas score 3 in 33%. Neither the vascular risk factors and diseases, the FSRP score, nor cerebrovascular disease was associated with disease progression in AD. Although vascular risk factors and vascular diseases were prevalent, no impact on the progression of AD after 2 years was shown.